Zydus Cadila receives final approval from USFDA for Mesalamine Delayed-Release Tablets

25 Jul 2017 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) for Mesalamine Delayed-Release Tablets in the strength of 800 mg. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.

The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

953.50 20.10 (2.15%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.